Paediatric research in the times of COVID-19

Paul F Fleming1,2, Chris Gale3,4, Eleanor J Molloy5,6,7

  • 1Homerton University Hospital, NHS Foundation Trust, London, UK.

Pediatric Research
|April 21, 2021
PubMed

Insights

The COVID-19 pandemic impacts children's health research, necessitating streamlined, collaborative approaches. Ensuring children's early inclusion in trials is crucial for future pediatric health advancements.

Area of Science:

  • Pediatric Health Research
  • Infectious Disease Epidemiology
  • Global Health Policy

Background:

  • The COVID-19 pandemic presents significant challenges to pediatric health research, affecting trial participation and funding.
  • Disruptions caused by the pandemic necessitate adaptive strategies for ongoing and future research endeavors.
  • Economic downturns may further impact the financial resources available for crucial child health studies.

Purpose of the Study:

  • To outline the direct and indirect consequences of the COVID-19 pandemic on children's health research.
  • To emphasize the importance of collaborative, networked, and technologically advanced research methods.
  • To provide recommendations for optimizing research governance, data sharing, and trial design for pediatric populations.

Main Methods:

  • Review of pandemic-related impacts on pediatric research activities.
  • Analysis of collaborative research models and remote technologies in clinical trials.
  • Synthesis of expert recommendations for research governance and trial development.

Main Results:

  • Streamlined research processes and remote technologies have been vital in mitigating COVID-19's impact.
  • Collaborative and networked research efforts have proven essential for reducing morbidity and mortality.
  • The pandemic highlights the need for efficient research governance and data sharing.

Conclusions:

  • Maintaining efficient research governance and data sharing is critical for high-quality collaborative research.
  • Early inclusion of children in relevant therapeutic trials is imperative.
  • Paediatric Research Societies must coordinate multinational trials for diagnostics, therapeutics, and preventative strategies.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
64
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
72
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
90
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
71
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
74
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.6K